ストックスクリーナーアプリを入手
653.45
0.01%
-0.595
前日終値:
$654.04
開ける：
$649.45
24時間の取引高:
240.49K
Relative Volume:
0.23
時価総額：
$68.04B
収益：
$14.25B
当期純損益:
$4.58B
株価収益率:
15.64
EPS:
41.7701
ネットキャッシュフロー:
$3.88B
1週間 パフォーマンス:
+13.16%
1か月 パフォーマンス:
+16.31%
6か月 パフォーマンス:
+9.22%
1年 パフォーマンス:
-21.98%
1日の値動き範囲:
$645.00
$660.00
1週間の範囲:
$575.93
$664.00
52週間の値動き範囲:
$476.49
$862.00
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
653.12 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.44 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.84 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
813.89 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
190.15 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Dupixent wins 2025 Prix Galien USA Best Biotechnology Product award - PharmaLive
UNIVEST FINANCIAL Corp Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer - BioSpace
Libtayo® (cemiplimab for injection) Now Reimbursed in Seven Provinces for Advanced Non-Small Cell Lung Cancer and Locally Advanced Basal Cell Carcinoma - BioSpace
Retirement Systems of Alabama Has $67.81 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals' Dupixent® Awarded "Best Biotechnology Product" by Galien Foundation for 2025 - Quiver Quantitative
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award - Caledonian Record
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award - GlobeNewswire Inc.
Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callCPI Data & Reliable Breakout Forecasts - newser.com
News impact scoring models applied to Regeneron Pharmaceuticals Inc.Market Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential - The Manila Times
Using fundamentals and technicals on Regeneron Pharmaceuticals Inc.Long Setup & Technical Entry and Exit Alerts - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsTrade Volume Summary & Low Volatility Stock Suggestions - newser.com
How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
Why Regeneron Pharmaceuticals Inc. stock is considered a top pickEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - Insider Monkey
Biopharma stocks regain ground in Q3 but still lag major indexes - BioWorld MedTech
Citigroup Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $708.00 at Royal Bank Of Canada - MarketBeat
Regeneron receives FDA CRL, delaying Eylea HD sBLA approval - Eyes On Eyecare
Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Cantor Fitzgerald Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $740.00 - MarketBeat
Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $865.00 at Guggenheim - MarketBeat
In a $1B+ deal, Modex joins with Regeneron to develop antibodies - BioWorld MedTech
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsTrade Exit Report & Verified Swing Trading Watchlists - newser.com
Regeneron (REGN) Margin Dip Underscores Market Caution Despite Strong Relative Valuation - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Evergreen Wealth Management LLC - MarketBeat
Wealthfront Advisers LLC Sells 1,560 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlphaQuest LLC - MarketBeat
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com
What MACD signals say about Regeneron Pharmaceuticals Inc.July 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
Combining price and volume data for Regeneron Pharmaceuticals Inc.Market Performance Report & Long-Term Capital Growth Strategies - newser.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue $0.88 Quarterly Dividend - MarketBeat
Regeneron receives another CRL for its Eylea 8 mg - Ophthalmology Times
Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar
REGN Receives Analyst Rating Boost with New Price Target | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (REGN) Sees Revised Price Target by RB - GuruFocus
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback (REGN) - Seeking Alpha
Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence - TipRanks
Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? - Barron's
Market Starting To Embrace The 'New' Regeneron (NASDAQ:REGN) - Seeking Alpha
Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies - Fierce Biotech
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up Following Earnings Beat - MarketBeat
Wells Fargo Raises Regeneron (REGN) Price Target Amidst Equal-We - GuruFocus
Regeneron teams up with Gary Nabel’s ModeX on multispecifics - Endpoints News
Cantor Fitzgerald Boosts Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results, Beats Estimates By $2.10 EPS - MarketBeat
Guggenheim Raises Regeneron Pharmaceuticals (REGN) Price Target to $865 | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
Regeneron Pharmaceuticals Inc (REGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SING GEORGE L | Director |
Dec 31 '24 |
Option Exercise |
413.33 |
3,338 |
1,379,696 |
29,610 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.37%
0.67%
大文字化:
|
ボリューム (24 時間):